Q-omics provides the consensus-scored NADSYN1 profile across patient tissues and cancer cell-line models. NADSYN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NADSYN1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, NADSYN1 RNA expression shows 18,535 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where NADSYN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NADSYN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NADSYN1 survival associations across molecular data types. NADSYN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NADSYN1 RNA expression–survival associations across cancer types. High NADSYN1 expression shows unfavorable associations in KICH, KIRC, ACC, LIHC and LGG, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for NADSYN1 RNA expression.
This table summarizes NADSYN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NADSYN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NADSYN1 shows higher tumor expression in KIRC, LIHC, STAD, THCA, UCEC and KIRP. The KIRC box plot shows higher NADSYN1 RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with NADSYN1 in patient tissues and cancer cell lines. In patient samples, NADSYN1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NADSYN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
